Most Recent Reports on Medical Devices Industry by GBI Research
13 Jan 2012 • by Natalie Aster
Oncology Devices Market to 2017 - Improved Efficiency, Shorter Treatment Times and Cost-Effectiveness to Boost the Brachytherapy Devices Segment. The global brachytherapy devices market is expected to grow at an annual rate of 2.2% from 2010 - 2017 to reach $301m by 2017, as increasing numbers of patients and oncologists opt for this therapy where as, The global endoscopic instruments market is expected to decrease at an annual rate of 1.9% from 2010 - 2017 to reach $77.2m by 2017.
Rapidly aging populations, changing dietary habits, lifestyle problems such as high-fat diets, high smoking rates and so on are generally considered to be responsible for a high incidence of cancer. Brachytherapy offers many benefits to patients who are increasingly opting for this non-invasive option. This will continue to drive the demand for brachytherapy in the future.
Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Greater Focus on Minimally Invasive Orthopedic Procedures to Drive the Market. The market for orthopedic devices in the emerging countries (China, India and Brazil) is expected to grow at a Compound Annual Growth Rate (CAGR) of 8%, reaching revenue of $3.1 billion in 2017.
In 2010, the orthopedic devices market in China, Brazil and India is valued at $879m, $575.6m and $385.6m respectively. These markets are expected to reach $1.5 billion, $778.6m and $878.3m respecticely by 2017. Cost-effective, high-quality care and better facilities without lengthy waiting periods make emerging countries such as India and Brazil as an attractive medical tourism destination for foreign patients.
Transcatheter Heart Valve Market to 2017 - Improvements in Design and Technique and a Favorable Reimbursement Scenario to Contribute to Higher Procedure Volumes. The global transcatheter heart valve market is expected to reach $1,196m in 2017. The market is forecast to grow with a Compounded Annual Growth Rate (CAGR) of 22% from $293.1m in 2010 to $1196m in 2017.
Degenerative calcified aortic stenosis is the most frequent heart valve disease in Europe and other Western countries. Calcification and thickening of the aortic valve is found to occur in 2-4% of adults over the age of 65. Transcatheter Aortic Valve Implantation (TAVI) provides elderly and high risk patients with a treatment option for heart valve replacement and the increasing elderly population is contributing to the growth of this market.
Published: January 2012
Price Per Report: $3.500,00 (Single User License)
More new market research reports by can be found at GBI Research page.
To order the report or ask for sample pages contact [email protected]